

Special Issue

Delivery of Oligonucleotide Therapeutics

Message from the Guest Editors

Oligonucleotide therapeutics (OTs) are synthetic DNA or RNA strands with the potential to treat a wide range of diseases. Until now, fifteen FDA-approved oligonucleotide drugs have been released on the market, with many other OTs being investigated. OTs are promising candidates in the pharmaceutical context. Nevertheless, one of the greatest challenges in oligonucleotide therapy is the delivery of the active substances to the site of action, mainly due to their unfavorable pharmacokinetic profile and nuclease degradation. To overcome these issues, many strategies have been reported in the literature, ranging from chemical modifications of the DNA/RNA backbone to bioconjugation or encapsulation in nanocarriers. The continuous progress in this field is gradually unlocking the true potential of oligonucleotide-based therapeutics, opening new perspectives and expanding the range of possible applications. Authors are invited to submit original papers, communications and reviews regarding the delivery of oligonucleotide therapeutics.

Guest Editors

Dr. Domenica Musumeci

Dr. Ettore Napolitano

Dr. Anna Di Porzio

Deadline for manuscript submissions

closed (20 December 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/194666

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).